Targeted Therapy Improves Survival in Poor-Risk Renal Cancer
Patients with poor-risk renal cell carcinoma have improved survival with temsirolimus (Torisel) whether they have a nephrectomy or not.03/04/2009
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Kidney Cancer | Nephrectomy | Renal Cell Carcinoma | Urology & Nephrology